Clostridioides difficile infection: antimicrobial prescribing
In development [GID-NG10144] Expected publication date: 23 July 2021
Search results
497 results
-
-
Skin abscess: antimicrobial prescribing
In development [GID-NG10163] Expected publication date: TBC
-
Stye: antimicrobial prescribing
In development [GID-NG10167] Expected publication date: TBC
-
Blepharitis: antimicrobial prescribing
In development [GID-NG10168] Expected publication date: TBC
-
Conjunctivitis: antimicrobial prescribing
In development [GID-NG10166] Expected publication date: TBC
-
Integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (update of DG21) (provisional title)
In development [GID-DG10042] Expected publication date: 13 April 2022
-
PredictSURE IBD and IBDX to guide treatment of Crohn's disease
In development [GID-DG10029] Expected publication date: TBC
-
Perineal biopsy devices for diagnosis of prostate cancer in people with suspected prostate cancer [provisional title]
In development [GID-DG10043] Expected publication date: TBC
-
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests
In development [GID-DG10038] Expected publication date: 06 January 2021
-
SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of bile acid diarrhoea
In development [GID-DG10039] Expected publication date: 17 November 2021
-
PlGF-based testing to help diagnose suspected pre-eclampsia (Update of DG23)
In development [GID-DG10040] Expected publication date: 17 November 2021
-
Quantitative faecal immunochemical tests to guide colorectal cancer pathway referral for people with a change in bowel habit or abdominal pain
In development [GID-DG10036] Expected publication date: TBC
-
QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography
In development [GID-DG10034] Expected publication date: TBC
-
EarlyCDT Lung for lung cancer risk classification of solid pulmonary nodules
In development [GID-DG10041] Expected publication date: 23 February 2022
-
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]
In development [GID-TA10611] Expected publication date: TBC
-
Bulevirtide for treating chronic hepatitis D [ID3732]
In development [GID-TA10652] Expected publication date: 20 October 2021
-
Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617
In development [GID-TA10545] Expected publication date: 21 April 2021
-
Andexanet alfa for reversing anticoagulation [ID1101]
In development [GID-TA10440] Expected publication date: 14 April 2021
-
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]
In development [GID-TA10561] Expected publication date: TBC
-
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]
In development [GID-TA10653] Expected publication date: TBC
-
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) [ID1585]
In development [GID-TA10538] Expected publication date: TBC
-
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
In development [GID-TA10711] Expected publication date: 15 September 2021
-
Non-bisphosphonates for treating osteoporosis [ID901]
In development [GID-TA10072] Expected publication date: TBC
-
Mepolizumab for previously treated severe chronic rhinosinusitis with nasal polyps [ID3817]
In development [GID-TA10701] Expected publication date: 20 July 2022
-
Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]
In development [GID-TA10669] Expected publication date: 04 May 2022
-
Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma [ID1625]
In development [GID-TA10643] Expected publication date: 16 June 2021
-
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]
In development [GID-TA10705] Expected publication date: 17 November 2021
-
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma [ID3862]
In development [GID-TA10744] Expected publication date: TBC
-
Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]
In development [GID-TA10742] Expected publication date: 05 January 2022
-
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]
In development [GID-TA10122] Expected publication date: TBC
-
Cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer [ID3839]
In development [GID-TA10725] Expected publication date: TBC
-
Pembrolizumab in combination for untreated, locally recurrent inoperable or metastatic, triple negative breast cancer [ID1546]
In development [GID-TA10417] Expected publication date: 15 September 2021
-
Pembrolizumab with platinum-based chemotherapy for untreated advanced oesophageal cancer [ID3741]
In development [GID-TA10613] Expected publication date: 13 October 2021
-
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]
In development [GID-TA10606] Expected publication date: 08 June 2022
-
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations [ID3761]
In development [GID-TA10630] Expected publication date: 23 March 2022
-
Third molars (impacted) - prophylactic removal [ID898]
In development [GID-TAG525] Expected publication date: TBC
-
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]
In development [GID-TA10664] Expected publication date: TBC
-
Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]
In development [GID-TA10470] Expected publication date: TBC
-
Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (Review of TA397) [ID1591]
In development [GID-TA10626] Expected publication date: 21 July 2021
-
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer (CDF Review of TA557) [ID1584]
In development [GID-TA10529] Expected publication date: 10 March 2021
-
Tebentafusp for treating metastatic or unresectable HLA-A*02:01 positive uveal melanoma [ID1441]
In development [GID-TA10428] Expected publication date: 20 July 2022
-
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1498
In development [GID-TA10420] Expected publication date: 23 June 2021
-
Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]
In development [GID-TAG496] Expected publication date: TBC
-
Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]
In development [GID-TAG494] Expected publication date: TBC
-
Diabetes - buccal insulin [ID311]
In development [GID-TAG244] Expected publication date: TBC
-
Cardiac transplantation (rejection) - everolimus [ID114]
In development [GID-TAG232] Expected publication date: TBC
-
Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer ID1605
In development [GID-TA10488] Expected publication date: TBC
-
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]
In development [GID-TA10024] Expected publication date: 28 June 2017
-
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]
In development [GID-TA10046] Expected publication date: 22 November 2017
-
Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]
In development [GID-TAG363] Expected publication date: TBC